Eli Lilly and Company
Targeted treatment of mature T-cell lymphoma
Last updated:
Abstract:
A method and medicament comprising 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d- ][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide or a pharmaceutically acceptable salt or hydrate thereof for treating aggressive peripheral T-cell lymphoma is provided.
Status:
Grant
Type:
Utility
Filling date:
6 Oct 2017
Issue date:
5 Jul 2022